Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene01:13

Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene

Bromination and chlorination of aromatic rings by electrophilic aromatic substitution reactions are easily achieved, but fluorination and iodination are difficult to achieve. Fluorine is so reactive that its reaction with benzene is difficult to control, resulting in poor yields of monofluoroaromatic products. To address this, Selectfluor reagent is used as a fluorine source in which a fluorine atom is bonded to a positively charged nitrogen.
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Halogens03:01

Halogens

Group 17 elements, known as halogens, are nonmetals. At room temperature, fluorine and chlorine are gases, bromine is a liquid, and iodine a solid. Astatine is a highly unstable radioactive element, so currently, most of its properties are unknown due to its short half-life. Tennessine is a synthetic element also predicted to be in this group.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy and safety of dupilumab in patients enrolled from Latin American centers from the open-label extension LIBERTY ASTHMA TRAVERSE study.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.

The journal of allergy and clinical immunology. Global·2026
Same author

Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.

Advances in therapy·2026
Same author

Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry.

Allergy·2025
Same author

Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial.

American journal of respiratory and critical care medicine·2025
Same author

Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE.

The Journal of allergy and clinical immunology·2025

Related Experiment Video

Updated: Jul 17, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

Fluorofelbamate.

Bryan A Roecklein1, Harry J Sacks, Henry Mortko

  • 1MedPointe Pharmaceuticals, Somerset, New Jersey 08873, USA. BRoecklein@medpointpharma.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary

New anticonvulsant therapies are needed for refractory seizures, as current options have limitations. Fluorofelbamate shows promise as a broad-spectrum option with a potentially improved safety profile.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Refractory seizures affect 30-40% of patients despite new anticonvulsants.
  • Current combinatorial therapies present administration and tolerability challenges.
  • Felbamate, while effective, carries risks of idiosyncratic toxicity.

Purpose of the Study:

  • To introduce fluorofelbamate as a novel anticonvulsant candidate.
  • To highlight its potential for broad-spectrum, multi-mechanistic seizure control.
  • To address the need for well-tolerated therapeutic options for refractory epilepsy.

Main Methods:

  • Fluorofelbamate was designed to retain felbamate's efficacy.
  • Metabolic modifications aim to prevent the formation of toxic metabolites.

More Related Videos

Forebrain Electrophysiological Recording in Larval Zebrafish
06:00

Forebrain Electrophysiological Recording in Larval Zebrafish

Published on: January 24, 2013

Related Experiment Videos

Last Updated: Jul 17, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
09:24

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products

Published on: August 22, 2017

Forebrain Electrophysiological Recording in Larval Zebrafish
06:00

Forebrain Electrophysiological Recording in Larval Zebrafish

Published on: January 24, 2013

  • In vitro studies assessed its mechanism and safety profile.

    • Main Results:

    • Fluorofelbamate is a phase I drug candidate.
    • In vitro data suggest it avoids the production of reactive metabolites linked to toxicity.
    • It is part of a class of carbamates being developed for CNS disorders.

    Conclusions:

    • Fluorofelbamate represents a potential advancement in treating refractory seizures.
    • Its modified metabolism may offer an improved safety profile compared to felbamate.
    • Further clinical development is warranted to confirm efficacy and tolerability.